EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sustained rescue of seizure control in patients with highly refractory chronic epilepsy using empiric immunotherapy

Elisabeth Doran, Albert Kelly iD, Raluca Stanila iD, Laura Healy, Colin P Doherty

Epilepsia · 2025

DOI: 10.1111/epi.18417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Elisabeth Doran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, St James's Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Immunotherapy, Seizures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Following emerging evidence of autoimmune‐associated seizures in medication‐refractory epilepsy, we began offering a trial of immunotherapy to selected patients. Here, we review this approach's treatment response, predictive clinical features, and utility.

Methods

This was a retrospective single‐center cohort study (2018–2022) of empiric, palliative immunotherapy in 31 adults with highly refractory, highly active epilepsy. Since 2018, in line with the International League Against Epilepsy's addition of “immune” as an etiology in the Classification of Epilepsy, we initiated immunotherapy after comprehensive antiseizure medication failures while at the same time screening for an autoimmune origin. The workup included assessing clinical features, serum autoantibody testing, cerebrospinal fluid testing (where feasible), magnetic resonance imaging (MRI), and electroencephalography. All patients received intravenous methylprednisolone or IV immunoglobulin according to previously published protocols, and follow‐up was for at least 12 months.

Results

Nine patients (29%) in this highly refractory cohort demonstrated a sustained treatment response, measured as a greater than 50% improvement in seizure frequency for at least 12 months. Three patients (10%) became seizure‐free. Six patients (20%) were classified as partial responders and experienced an initial response that was not sustained. Apart from a trend toward a diagnosis of focal epilepsy, we did not identify any specific serological, clinical, electrodiagnostic, or imaging features with statistical significance that were predictive of treatment response. Significance This patient group demonstrated a reasonable response rate to an immunotherapy trial. These findings are surprising but support the consideration of an immunotherapy trial in patients with refractory epilepsy. Requirements for repeated courses of immunotherapy differed significantly between patients, and this is an area of interest for further research. The basis for response in this cohort remains unclear; in some cases, antiseizure medication changes may have contributed; however, without any apparent autoimmune features, we consider potential blood–brain barrier repair or a placebo effect as hypothetical alternative mechanisms of action for the response to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyImmunotherapySeizuresAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAutoantibodiesChronic DiseaseElectroencephalographyFollow-Up StudiesGlucocorticoidsImmunoglobulins, IntravenousImmunologic FactorsMagnetic Resonance ImagingMethylprednisoloneRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

autoimmuneblood–brain barrierimmunotherapyrefractory epilepsy

Substanzen

AutoantibodiesGlucocorticoidsImmunoglobulins, IntravenousImmunologic FactorsMethylprednisolone

Autor:innen und Institutionen

  • Department of Neurology, St James's Hospital, Dublin, Ireland.
  • The Academic Unit of Neurology, Trinity College School of Medicine, Dublin, Ireland.
  • The FutureNeuro Research Ireland Centre for Translational Brain Science, The Royal College of Surgeons Ireland, Dublin, Ireland.

ORCID-Profile: Albert Kelly, Raluca Stanila

Zitieren

APA

Doran, E., Kelly, A., Stanila, R., Healy, L., & Doherty, C. P. (2025). Sustained rescue of seizure control in patients with highly refractory chronic epilepsy using empiric immunotherapy. Epilepsia. https://doi.org/10.1111/epi.18417

Vancouver

Doran E, Kelly A, Stanila R, Healy L, Doherty CP. Sustained rescue of seizure control in patients with highly refractory chronic epilepsy using empiric immunotherapy. Epilepsia. 2025. doi:10.1111/epi.18417

BibTeX
@article{Doran2025,
  author = {Doran, Elisabeth and Kelly, Albert and Stanila, Raluca and Healy, Laura and Doherty, Colin P},
  title = {Sustained rescue of seizure control in patients with highly refractory chronic epilepsy using empiric immunotherapy},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18417}
}
Kostenlos starten →